Re: Please, Lord
Penny love and blessings to you and showing us the way of courage and faith xxoo Lois
|
Re: Please, Lord
Penny,
Thinking of you all day as I have watched the crazy weather out my library windows here in Chicago. We have had tumultuous clouds crossing the sky followed by bright sunshine, then patchy downpours and sunshine again - very much an analogy for this cancer journey we have been forced to take. I hope your days are filled with more sunshine that downpours : ). Praying for you, Cindy |
Re: Please, Lord
Penny my thoughts & prayers are with you and your family.
|
Re: Please, Lord
I prayed for you, Penny, today. May our Lord keep you under his care.
|
Re: Please, Lord
Penny, thinking of you today, saying a prayer. Love you sweetheart.
|
Re: Please, Lord
Penny,
I am holding you in prayer. Love, Amy |
Re: Please, Lord
Thank You, Lord. Bilirubin came down @ 3 points. Chemo today. Off next week. Please continue to pray. Thanks!
- Penny |
Re: Please, Lord
We'll take every blessing Penny - keeping you in my prayers that chemo does it's work.....
Marie |
Re: Please, Lord
So grateful and glad to hear from you, Penny. Praying for you, keep those numbers coming down!
Carol Ann |
Re: Please, Lord
Penny , This situation reminds me of a song from the early 70s
Put your hand in a hand. by the Oceans https://www.youtube.com/watch?v=f1iAaKHd7z8 |
Re: Please, Lord
Penny prayers still continue for you.
|
Re: Please, Lord
Stay strong!!!
|
Re: Please, Lord
Praying for you my dear sister in Christ.
|
Re: Please, Lord
Hi, Penny,
You are RIGHT there: Abramson Cancer Center. My integrative doctor has been using Keytruda on a non-breast or non-melanoma metastatic patient and his recovery has been astounding. He's battled lung cancer mets to *everywhere* and Keytruda has wiped it out of his body. Check this out: Keytruda® with Hypofractionated Radiotherapy for Metastatic Breast Cancer RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers (NCT02303990) Summary The immunotherapy pembrolizumab (Keytruda®) targets programmed cell death 1 (PD-1), a receptor that keeps the immune system from attacking cancer cells. It is approved for treating metastatic melanoma and is being studied in metastatic breast and other cancers. Hypofractionated radiation delivers larger doses of radiation in less amount of time than standard radiation therapy. This trial is investigating the effectiveness of using hypofractionated radiotherapy in combination with Keytruda for treating metastatic breast (and other advanced) cancers that have progressed on at least one prior therapy. This is a Phase I trial Love you, girl Karen |
Re: Please, Lord
So very glad to hear the good news, Penny! Thankful for answered prayers!
|
Re: Please, Lord
Sending prayers and healing thoughts to you each and every day Penny!
|
Re: Please, Lord
Thinking of ypu always.
|
Re: Please, Lord
Praying for strength, peace and healing dear Penny!!!
|
Re: Please, Lord
Keep the faith - dont give up
|
Re: Please, Lord
Sending prayers
|
Re: Please, Lord
Penny,
I pray for you every day. Love and blessings, Amy |
Re: Please, Lord
Penny,
Thinking of you and sending prayers. Cindy |
Re: Please, Lord
Penny, Wondering how you are doing??? Please let us know.
Still praying for you. |
Re: Please, Lord
Hey, Penny, another with Keytruda! I've seen this drug in action! This one is in AZ. Best of luck.
Love Karen NEW Keytruda with Herceptin or Kadcyla in Advanced Breast (and Other) Cancer A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab (NCT02318901) Summary Pembrolizumab (Keytruda®) is a new immunotherapy agent that works by blocking a protein called programmed cell death (PD-1) that normally keeps the body's immune system from attacking and destroying tumor cells. It has recently approved for treating metastatic melanoma and may also be effective in other types of cancer. Ado-trastuzumab ematansine/T-DM1 (Kadcyla®) is a HER2-targeted therapy that combines the chemotherapy drug DMI with the HER2-targeted therapy trastuzumab (Herceptin®). In patients with HER2+ metastatic breast cancer, this study will compare the safety and effectiveness of Keytruda and Herceptin with Keytruda and Kadcyla. Patients with other types of cancers will be enrolled in different arms of the study. This is a Phase I-II trial |
All times are GMT -7. The time now is 10:17 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021